Vol.53 No.6 June 2005
Antimicrobial activity surveillance of various clinical isolates to tosufloxacin and other fluoroquinolones
Chemotherapy Division, Mitsubishi Kagaku Bio-Clinical Laboratories, Inc.,
3-30-1 Shimura, Itabashi-ku, Tokyo, Japan
Abstract
We determined the susceptibility of bacteria which were isolated from patients with various infections nationwide between 2003 and 2004, to tosufloxacin (TFLX) and other fluoroquinolones. The antimicrobial activity of TFLX against Staphylococcus except methicillin-resistant Staphylococcus aureus was potent and nearly the same as that of gatifloxacin (GFLX). TFLX showed the most potent antimicrobial activity against Streptococcus including penicillin-resistant Streptococcus pneumoniae of fluoroquinolones. These fluoroquinolones showed potent antimicrobial activity against Moraxella (Branhamella) catarrhalis and Haemophilus influenzae. Second only to GFLX, TFLX showed the potent antimicrobial activity against Mycoplasma pneumoniae, and TFLX showed the most potent antimicrobial activity against Legionella pneumophila among fluoroquinolones tested. Second only to GFLX, TFLX showed potent antimicrobial activity against Chlamydia pneumoniae and Chlamydia trachomatis. These results indicate that TFLX shows excellent antimicrobial activity against all fresh strains isolated from patients with infections. TFLX is thus useful as a therapeutic antimicrobial for treating a variety of infections.
Key word
tosufloxacin, antibacterial activity, clinical isolate
Received
December 17, 2004
Accepted
April 19, 2005
Jpn. J. Chemother. 53 (6): 364-370, 2005
